Safety, efficacy, and clinical utility of the 5.1-mm debridement catheter for treatment of walled-off pancreatic necrosis (with video).

Background and Aims: Direct endoscopic necrosectomy (DEN) is a recommended strategy for treatment of walled-off necrosis (WON). DEN uses a variety of devices including the EndoRotor (Interscope, Inc, Northbridge, Mass, USA) debridement catheter. Recently, a 5.1-mm EndoRotor with an increased chamber size and rate of tissue removal was introduced. The aim of this study was to assess the efficacy and safety of this device.
Methods: A multicenter cohort study was conducted at 8 institutions including patients who underwent DEN with the 5.1-mm EndoRotor. The primary outcome was the number of DEN sessions needed for WON resolution. Secondary outcomes were the average percentage of reduction in solid WON debris and decrease in WON area per session, total time spent performing EndoRotor therapy for WON resolution, and adverse events (AEs).
Results: Sixty-four procedures in 41 patients were included. For patients in which the 5.1-mm EndoRotor catheter was the sole therapeutic modality, an average of 1.6 DEN sessions resulted in WON resolution with an average cumulative time of 85.5 minutes. Of the 21 procedures with data regarding percentage of solid debris, the average reduction was 85% ± 23% per session. Of the 19 procedures with data regarding WON area, the mean area significantly decreased from 97.6 ± 72.0 cm ² to 27.1 ± 35.5 cm ² (P < .001) per session. AEs included 2 intraprocedural dislodgements of lumen-apposing metal stents managed endoscopically and 3 perforations, none of which was related to the EndoRotor. Bleeding was reported in 7 cases, in which none required embolic or surgical therapy and 2 required blood transfusions.
Conclusions: This is the first multicenter retrospective study to investigate the efficacy and safety of the 5.1-mm EndoRotor catheter for WON. Results from this study showed an average of 1.6 DEN sessions were needed to achieve WON resolution with an 85% single-session reduction in solid debris and a 70% single-session decrease in WON area with minimal AEs.
Competing Interests: Disclosure The following authors disclosed financial relationships: J. H. Hwang: Consultant for Boston Scientific, Olympus, Medtronic, Lumendi, MicroTech, Noah Medical, and Ovesco. S. El-Dika: Consultant for Medtronic. S. Krishna: Research support from Mauna Kea Technologies and TaeWoong Medical USA. M. A. Khashab: Consultant for Pentax, GI Supply, Apollo, Boston Scientific, Olympus, and Medtronic. A. Kumar: Consultant for Olympus. A. Chiang: Consultant for Boston Scientific, Exact Sciences, Olympus, Moderna, and YouTube; employee of Medtronic. A. Schlachterman: Consultant for Olympus, Fujifilm, Lumendi, ConMed, and Medtronic. D. Loren: Consultant for Boston Scientific, Olympus America, and Ambu. T. Kowalski: Consultant for Boston Scientific. All other authors disclosed no financial relationships.
(Copyright © 2024 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.)